Nader Sanai

Brigham and Women's Hospital — United States

Medicine · Health Sciences

60h-index18.3kcitations379works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(189), Meningioma and schwannoma management(66), Vascular Malformations Diagnosis and Treatment(25), Cancer Genomics and Diagnostics(24), Advanced Breast Cancer Therapies(24)

Publications372 total

An early clinical trial of 5-ALA sonodynamic therapy in recurrent high-grade glioma
Science Translational Medicine·2025
Single-nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a Phase 0/1 trial of recurrent high-grade glioma
Neuro-Oncology·2025· 2 citedOpen Access
RBIO-17. The radioprotective effect of a novel brain-penetrant superoxide dismutase mimic on normal brain
Neuro-Oncology·2025Open Access
RBIO-15. Diverse redox states underpin glioblastoma heterogeneity in preclinical models and patient samples
Neuro-Oncology·2025Open Access
EPCO-58. SINGLE-CELL PROFILING REVEALS CELLULAR DIVERSITY AND A STEM-LIKE COMPARTMENT IN SUBEPENDYMOMA
Neuro-Oncology·2025Open Access
EXTH-132. Evaluation of TEAD inhibitor, VT3989, treatment in aggressive meningioma
Neuro-Oncology·2025Open Access
CTNI-14. INTEGRATED PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL DATA UPDATE FROM PHASE 0/1 TRIAL FOR BDTX-1535 IN NEWLY-DIAGNOSED AND RECURRENT GLIOBLASTOMA PATIENTS WITH EGFR ALTERATIONS
Neuro-Oncology·2025Open Access
SURG-17. A comprehensive framework for intraoperative mapping and monitoring, and perioperative neurological, linguistic, and outcome assessment in glioma resection: Consensus recommendations from the PIONEER Consortium and RANO resect group
Neuro-Oncology·2025Open Access
TIP-06. A global, open-label, randomized Phase 3 trial evaluating niraparib compared to standard temozolomide therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma
Neuro-Oncology·2025Open Access
TIP-09. A phase 0/1 study of PRMT5 inhibitor BMS-986504 in recurrent glioblastoma participants with MTAP deletion
Neuro-Oncology·2025
DDDR-68. HDAC inhibition–induced neuronal-like state creates cytoskeletal vulnerabilities in glioblastoma
Neuro-Oncology·2025Open Access
Neuro-pharmacokinetic assessment of manganese porphyrin-based superoxide dismutase mimics
Free Radical Biology and Medicine·2025
P17.21.A DETERMINATION OF TOTAL AND UNBOUND LEVELS OF A POTENT WEE1 INHIBITOR, ZN-C3, IN HUMAN PLASMA, CSF, AND BRAIN TUMOR BY A VALIDATED LC-MS/MS METHOD.
Neuro-Oncology·2025Open Access
OS11.6.A A COMPREHENSIVE FRAMEWORK FOR INTRAOPERATIVE MAPPING AND MONITORING, AND PERIOPERATIVE NEUROLOGICAL, LINGUISTIC, AND OUTCOME ASSESSMENT IN GLIOMA RESECTION: CONSENSUS RECOMMENDATIONS FROM THE PIONEER CONSORTIUM AND RANO RESECT GROUP
Neuro-Oncology·2025Open Access
P01.13.A MECHANISMS OF RADIOSENSITIZATION AND RESISTANCE FOLLOWING HDAC INHIBITION IN GBM PRECLINICAL MODELS.
Neuro-Oncology·2025Open Access
P12.28.A A CLINICAL UPDATE OF A FIRST-IN-HUMAN PHASE 0/1 TRIAL OF 5-AMINOLEVULINIC ACID SONODYNAMIC THERAPY (5-ALA SDT) IN RECURRENT GLIOBLASTOMA.
Neuro-Oncology·2025Open Access
P12.25.B A GLOBAL PHASE 3, OPEN-LABEL, RANDOMIZED-CONTROLLED STUDY FOR NEWLY-DIAGNOSED, MGMT UNMETHYLATED GLIOBLASTOMA, COMPARING NIRAPARIB VS STANDARD OF CARE TEMOZOLOMIDE TREATMENT.
Neuro-Oncology·2025Open Access
P12.27.B A PHASE 0/1 STUDY OF PRMT5 INHIBITOR BMS-986504 IN RECURRENT GLIOBLASTOMA PARTICIPANTS WITH MTAP DELETED TUMORS.
Neuro-Oncology·2025Open Access
P12.29.B PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL DATA UPDATE FROM PHASE 0/1 TRIAL FOR BDTX-1535 IN RECURRENT GLIOBLASTOMA PATIENTS WITH EGFR ALTERATIONS.
Neuro-Oncology·2025Open Access
Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas
2025· 1 citedOpen Access
page 1 of 19Next →

Frequent Co-authors

Mitchel S. Berger(18), Alfredo Quiñones‐Hinojosa(7), Robert F. Spetzler(7), Arturo Álvarez-Buylla(6), Stephen W. Coons(6), José Manuel García‐Verdugo(5), Kris A. Smith(5), Nalin Gupta(4), Zaman Mirzadeh(4), Peter Nakaji(4), Michael T. Lawton(4), Christopher F. Dowd(4), Andrew T. Parsa(3), Michael T. Lawton(3), Johan Pallud(3), Luc Bauchet(3), Denys Fontaine(3), Emmanuel Mandonnet(3), Jacques Guyotat(3), P Peruzzi(3)